Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer's Disease
Sources News Release

http://www.sources.com/Releases/NR1240.htm

Publisher:  Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written:  20/04/2011
Year Published:  2011  
Resource Type:  Article

Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.

Abstract:  Hoboken, NJ – April 20, 2011 - Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.

“We are pleased that the first volunteers have been dosed with the study drug, according to the study protocol, and no adverse events have been recorded post dosing to date," said Dr. Ozkan Yalkinoglou, Medical Director of ...
To read the full release go to http://www.sources.com/Releases/NR1240.htm

Topics


Sources-journalists use the sources website to find you


AlterLinks
c/o Sources


© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.